Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877)
Hong Kong
· Delayed Price · Currency is HKD
11.06
-0.14 (-1.25%)
Jan 3, 2025, 4:08 PM HKT
Shanghai Junshi Biosciences Revenue
Shanghai Junshi Biosciences had revenue of 485.14M CNY in the quarter ending September 30, 2024, with 53.16% growth. This brings the company's revenue in the last twelve months to 1.79B, up 46.31% year-over-year. In the year 2023, Shanghai Junshi Biosciences had annual revenue of 1.50B with 3.38% growth.
Revenue (ttm)
1.79B CNY
Revenue Growth
+46.31%
P/S Ratio
5.51
Revenue / Employee
695.99K CNY
Employees
2,568
Market Cap
24.05B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.50B | 49.06M | 3.38% |
Dec 31, 2022 | 1.45B | -2.57B | -63.89% |
Dec 31, 2021 | 4.02B | 2.43B | 152.36% |
Dec 31, 2020 | 1.59B | 819.81M | 105.77% |
Dec 31, 2019 | 775.09M | 774.16M | 82,885.99% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |